ClinConnect ClinConnect Logo
Search / Trial NCT05634109

Whole Blood in Trauma Patients With Hemorrhagic Shock

Launched by FUNDACION CLINICA VALLE DEL LILI · Nov 21, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Whole Blood Blood Transfusion Blood Component Transfusion Hemorrhage Advanced Trauma Life Support Care Hemostatic Resuscitation

ClinConnect Summary

This clinical trial is studying the best way to treat trauma patients who are experiencing severe blood loss, known as hemorrhagic shock. Researchers want to compare two methods of providing blood transfusions: using whole blood (which includes all components of blood) versus using separate blood components like red blood cells, plasma, and platelets. The main goals are to see which method leads to lower death rates within 28 days and better overall health of the organs affected by the trauma.

To be eligible for this trial, participants need to be adults over 18 years old who are experiencing severe bleeding from trauma and are likely to need a large amount of blood transfusion. They must also be able to receive either whole blood or blood component therapy. However, certain patients are excluded, such as those with very severe injuries, those who have already received multiple blood transfusions, or pregnant individuals. If someone joins the study, they will receive one of the two types of blood treatment and will be monitored closely for their recovery and any changes in their health.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult patients (\> 18 years)
  • Activating institutional trauma code for trauma patients with hemorrhagic shock.
  • Candidate for massive transfusion (Patient with an Assessment Blood Consumption (ABC) Score ≥ 2 or at the discretion of the treating physician)
  • Concurrent availability of whole blood or blood component therapy
  • Exclusion Criteria:
  • More than 4 hours from trauma to hospital admission
  • More than 2 hours from hospital admission to randomization
  • Transfusion of more than one packed red blood cell unit prior to randomization.
  • Patients who have undergone surgery (laparotomy, thoracotomy, or sternotomy) before hospital admission.
  • In-extremis patients with devastating injuries (expected to die within 60 minutes).
  • Blood group other than to O or A and positive Rh factor
  • Severe traumatic brain injury in which neurosurgical intervention is futile (partial decapitation, massive intracranial hemorrhage, or transcranial gunshot wounds).
  • Burns over 20% of the total body surface area.
  • Suspected airway burn.
  • Cardiopulmonary resuscitation (CPR) before arrival at the ED.
  • CPR for more than 5 minutes before randomization.
  • Do not resuscitate order.
  • Incarcerated/prisoners.
  • Known pregnancy in the ED.
  • Patient or legal representative who refuse to participate in clinical research studies.

About Fundacion Clinica Valle Del Lili

Fundación Clínica Valle del Lili is a leading healthcare institution located in Cali, Colombia, dedicated to advancing medical research and enhancing patient care through innovative clinical trials. As a sponsor, the foundation focuses on conducting high-quality, ethically-driven studies that contribute to the development of new treatments and therapies across various medical fields. With a commitment to excellence, the foundation collaborates with healthcare professionals and researchers to ensure rigorous methodologies and compliance with international standards, ultimately aiming to improve health outcomes and quality of life for diverse patient populations.

Locations

Cali, Valle Del Cauca, Colombia

Patients applied

0 patients applied

Trial Officials

Alberto F Garcia, MD MSc

Principal Investigator

Fundacion Clinica Valle del Lili

Carlos A Ordoñez, MD

Principal Investigator

Fundacion Clinica Valle del Lili

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials